Preferences help
enabled [disable] Abstract
Number of results
2015 | 5 | 1 | A33-A41
Article title

Post-transplant care after allogeneic hematopoietic stem cell transplantation

Title variants
Languages of publication
Around 25,000 people annually worldwide are subject to the procedure of allogeneic hematopoietic stem cell transplantation (HSCT). As the number of procedures has been on the rise, post-transplant care is becoming an essential part of work at transplant centres and general practitioners’ offices. Advances in technology and supportive therapies extend long-term survival of patients after HSCT, which increases the risk of complications resulting from exposure before, during and after transplant procedures. The complications may lead to significant morbidity, deteriorated quality of life, and late mortality in patients who have received hematopoietic stem cells. Statistical analyses have shown that the survival rate of post-HSCT patients is ca. 30% lower than expected, and that infections, organ failure and secondary cancers lead to mortality in this population of patients.
Physical description
  • Department of Haematology, Oncology and Internal Diseases, Medical University of Warsaw
  • Department of Haematology, Oncology and Internal Diseases, Medical University of Warsaw
  • The BMT Data Book, 2nd edition. Munkers R, Lazarus H, Atkinson K (ed.). Cambridge Medicine.
  • The EBMT Handbook, 6th edition, 2012. Apperley J, Carreras E, Gluckman E. (ed.).
  • Witt M, Szczepański T, Dawidowska M. Hematologia molekularna – patogeneza, patomechanizm i metody badawcze [Molecular haematology – pathogenesis, pathomechanism and research methods]. Ośrodek Wydawnictw Naukowych 2009.
  • Gołąb J, Jakóbisiak M, Lasek W et al. Immunologia [Immunology]. PWN, Warszawa 2008.
  • Guidelines BMT 2009; 44: 457-536.
  • Blazar B, Murphy W, Abedi M. Advances in graft-versus-host disease biology and therapy. Nature Reviews Immunology 2012; 12: 443-458.
  • Ferrar J, Levine J, Reddy P et al. Graft-versus-Host Disease. Lancet 2009; 2: 1550-1561.
  • Rubin L, Levin M, Ljungman P. 2013 IDSA Clinical Practice Guideline for Vaccination of the Immunocompromised host. Clinical Infectious Diseases 2014; 58: e44-e100.
  • Medycyna Praktyczna Szczepienia 2014/01 [Practical Medicine Journal – Vaccinations, 2014/01 issue].
  • Fry T, Mackall C. Immune reconstitution following hematopoietic progenitor cell transplantation; challenges for the future. BMT 2005; 35: S53-57.
  • Maury S, Mary J, Rabian C et al. Prolonged immune deficiency following allogeneic stem cell transplantation: risk factors and complications in adult patients. British Journal of Haematology 2001; 115(3): 630-641.
  • Mackall C, Fry T, Gress F et al. Background to hematopoietic cell transplantation, including post transplant immune recovery. BMT 2009; 44: 457-462.
  • Storek J, Dawson M, Storer B. Immune reconstitution after allogeneic marrow transplantation compared with blood stem cell transplantation. Blood 2001; 97(11): 3380-3389.
  • Lum L. The kinetics of immune reconstitution after human marrow transplantation. Blood 1987; 69: 369-380.
  • Seggewiss R, Einsele H. Immune reconstitution after allogeneic transplantation and expanding options for immunomodulation: an update. Blood 2010; 115(19): 3861-3868.
  • Tomblyn M, Chiller T, Einsele H et al. Guidelines for Preventing Infectious Complications among Hematopoietic Cell Transplantation Recipients: A Global Perspective. Biol Blood Marrow Transplant 2009; 15: 1143-1238.
  • Maertens J, Marchetti O, Herbrecht R et al. European guidelines for antifungal management in leukemia and hematopoietic stem cell transplant recipients: summary of the ECIL 3 – 2009 Update. Bone Marrow Transplantation 2011; 46: 709-718.
  • Zaia J, Baden L, Boeckh M. Viral disease prevention after hematopoietic cell transplantation. Bone Marrow Transplantation 2009; 44: 471-482.
  • Marr K, Bow E, Chiller T et al. Fungal infection prevention after hematopoietic cell transplantation. British Committee for Standards in Haematology; Guidelines on the management of invasive fungal infection during therapy for haematological malignancy, British Committee for Standards in Haematology. BMT 2009; 44: 483-487.
  • Gratwohl A, Brand R, Frassoni F et al. Cause of death after allogeneic haematopoietic stem cell transplantation (HSCT) in early leukemias: an EBMT analysis of lethal infectious complications and changes over calendar time. BMT 2005; 36: 757-769.
  • Jędrzejczak W. Aktualne wskazania do przeszczepienia komórek krwiotwórczych komórek macierzystych [Current indications for hematopoietic stem cell transplantation]. Acta Haematologica Polonica 2009; 40: 305-311.
Document Type
Publication order reference
YADDA identifier
JavaScript is turned off in your web browser. Turn it on to take full advantage of this site, then refresh the page.